BACKGROUND/AIM: Hepatic resection is not applicable to a certain proportion of hepatocellular carcinoma patients owing to an insufficient liver function reserve. The present study was designed to investigate the effects of cardiotrophin-1 (CT-1) on improving the function of CCl(4)-induced cirrhotic liver remnant after major hepatectomy. METHODS: CT-1 was administered to rats after hepatectomy according to different protocols. RESULTS: A double-dose CT-1 protocol improved liver function, enlarged the volume of liver remnant, upregulated the expression of von Willebrand factor and increased the number of BrdU(+) or Ki-67(+) hepatocytes. Administration of CT-1 enhanced the expression of nuclear factor-kappaB (P65), vascular endothelial growth factor (VEGF), CyclinD1 and p42/44 in the liver remnant. However, the effects of CT-1 were blocked by a VEGF receptor blocker, PTK787. Although the expression of gp130, a receptor of CT-1, was downregulated in the diseased hepatocytes isolated from the cirrhotic liver, CT-1 could still stimulate the cell proliferation. CT-1 administration enhanced the expression of P65 and VEGF in the diseased hepatocytes, but the augmented P65 and VEGF expression was blocked by PTK787 administration. CONCLUSION: Short-term administration of CT-1 could improve the function of cirrhotic liver remnant and stimulate liver regeneration through promotion of angiogenesis and cell proliferation.
BACKGROUND/AIM: Hepatic resection is not applicable to a certain proportion of hepatocellular carcinomapatients owing to an insufficient liver function reserve. The present study was designed to investigate the effects of cardiotrophin-1 (CT-1) on improving the function of CCl(4)-induced cirrhotic liver remnant after major hepatectomy. METHODS:CT-1 was administered to rats after hepatectomy according to different protocols. RESULTS: A double-dose CT-1 protocol improved liver function, enlarged the volume of liver remnant, upregulated the expression of von Willebrand factor and increased the number of BrdU(+) or Ki-67(+) hepatocytes. Administration of CT-1 enhanced the expression of nuclear factor-kappaB (P65), vascular endothelial growth factor (VEGF), CyclinD1 and p42/44 in the liver remnant. However, the effects of CT-1 were blocked by a VEGF receptor blocker, PTK787. Although the expression of gp130, a receptor of CT-1, was downregulated in the diseased hepatocytes isolated from the cirrhotic liver, CT-1 could still stimulate the cell proliferation. CT-1 administration enhanced the expression of P65 and VEGF in the diseased hepatocytes, but the augmented P65 and VEGF expression was blocked by PTK787 administration. CONCLUSION: Short-term administration of CT-1 could improve the function of cirrhotic liver remnant and stimulate liver regeneration through promotion of angiogenesis and cell proliferation.
Authors: Edina Bugyik; Katalin Dezso; Eszter Turányi; Kinga Szurián; Sándor Paku; Peter Nagy Journal: Int J Exp Pathol Date: 2012-01-14 Impact factor: 1.925
Authors: Carlos A Barrón-Gallardo; Mariel Garcia-Chagollán; Andres J Morán-Mendoza; Raul Delgadillo-Cristerna; María G Martínez-Silva; Adriana Aguilar-Lemarroy; Luis F Jave-Suárez Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec
Authors: Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos Journal: Nat Rev Gastroenterol Hepatol Date: 2021-07-01 Impact factor: 46.802
Authors: Matilde Bustos; Juan Dubrot; Eduardo Martinez-Anso; Eduardo Larequi; David Castaño; Asis Palazon; Idoia Belza; Miguel F Sanmamed; Jose Luis Perez-Gracia; Carlos Ortiz de Solorzano; Carlos Alfaro; Ignacio Melero Journal: Oncoimmunology Date: 2012-12-01 Impact factor: 8.110